LOVE TED W — SEC insider filings
SEC reporting owner CIK 1188919. 36 insider filings on record with FilingPulse; latest filed 2026-09-28.
Transaction summary — filings shown
Covers all 36 filings on record, filed 2020-08-17 to 2026-09-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 104.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Global Blood Therapeutics, Inc. (GBT) | President and CEO, Director | 12 | — | — | 68 |
| Seagen Inc. (SGEN) | Director | 5 | — | — | 13 |
| GILEAD SCIENCES, INC. (GILD) | Director | 4 | — | — | 8 |
| Royalty Pharma plc (RPRX) | Director | 7 | — | — | 7 |
| Jazz Pharmaceuticals plc (JAZZ) | Director | 3 | — | — | 4 |
| Structure Therapeutics Inc. (GPCR) | Director | 4 | — | — | 4 |
| LISATA THERAPEUTICS, INC. (LSTA) | Director | 1 | — | — | — |
Insider filings — LOVE TED W
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-28 | 3 | LISATA THERAPEUTICS, INC. (LSTA) | Holdings only — no transactions reported | EDGAR |
| 2026-09-02 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Tax withholding (F): 6 @ $244.06 · Tax withholding (F): 737 @ $241.39 | EDGAR |
| 2026-08-07 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-06-18 | 4 | Structure Therapeutics Inc. (GPCR) | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-05-04 | 4 | GILEAD SCIENCES, INC. (GILD) | Grant/award (A): 1,146 @ $0 · Grant/award (A): 4,884 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 1,527 @ $0 | EDGAR |
| 2025-06-25 | 4 | Structure Therapeutics Inc. (GPCR) | Grant/award (A): 51,804 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,614 @ $0 | EDGAR |
| 2025-05-08 | 4 | GILEAD SCIENCES, INC. (GILD) | Grant/award (A): 1,516 @ $0 · Grant/award (A): 6,809 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Structure Therapeutics Inc. (GPCR) | Grant/award (A): 33,595 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 9,293 @ $0 | EDGAR |
| 2024-05-09 | 4 | GILEAD SCIENCES, INC. (GILD) | Grant/award (A): 2,310 @ $0 · Grant/award (A): 12,648 (derivative) @ $0 | EDGAR |
| 2024-02-06 | 4 | GILEAD SCIENCES, INC. (GILD) | Grant/award (A): 512 @ $0 · Grant/award (A): 2,996 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Seagen Inc. (SGEN) | Disposition to issuer (D): 4,255 @ $229 · Disposition to issuer (D): 4,460 (derivative) · Disposition to issuer (D): 3,462 (derivative) · Disposition to issuer (D): 3,676 (derivative) · Disposition to issuer (D): 449 (derivative) · Disposition to issuer (D): 2,044 (derivative) | EDGAR |
| 2023-08-04 | 4 | Structure Therapeutics Inc. (GPCR) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,747 @ $0 | EDGAR |
| 2023-06-02 | 4 | Seagen Inc. (SGEN) | Grant/award (A): 2,044 @ $0 | EDGAR |
| 2022-10-06 | 4 | Global Blood Therapeutics, Inc. (GBT) | Disposition to issuer (D): 576,318 · Disposition to issuer (D): 119,650 · Disposition to issuer (D): 119,650 · Disposition to issuer (D): 102,000 · Disposition to issuer (D): 2,500 · Disposition to issuer (D): 2,500 · +12 more | EDGAR |
| 2022-09-29 | 4 | Global Blood Therapeutics, Inc. (GBT) | Gift (G): 221,200 @ $0 · Gift (G): 35,300 @ $0 · Gift (G): 17,650 @ $0 · Gift (G): 17,650 @ $0 · Option exercise (M): 18,291 @ $16.40 · Option exercise (M): 18,291 (derivative) @ $0 | EDGAR |
| 2022-09-06 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 9,444 · Option exercise (M): 9,109 · Tax withholding (F): 9,200 @ $68.15 · Option exercise (M): 9,444 (derivative) @ $0 · Option exercise (M): 9,109 (derivative) @ $0 | EDGAR |
| 2022-08-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 20,205 · Tax withholding (F): 10,018 @ $32.40 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 6,328 @ $0 | EDGAR |
| 2022-05-17 | 4 | Seagen Inc. (SGEN) | Grant/award (A): 1,503 @ $0 · Grant/award (A): 3,676 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Grant/award (A): 839 @ $25.37 · Option exercise (M): 9,445 · Tax withholding (F): 4,074 @ $29.87 · Option exercise (M): 9,445 (derivative) @ $0 · Grant/award (A): 72,877 (derivative) @ $0 · Grant/award (A): 72,877 (derivative) @ $0 · +1 more | EDGAR |
| 2022-02-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 29,955 · Tax withholding (F): 10,531 @ $29.33 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0 | EDGAR |
| 2022-01-06 | 4/A | Global Blood Therapeutics, Inc. (GBT) | Disposition to issuer (D): 24,821 @ $3.40 | EDGAR |
| 2021-09-24 | 4/A | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 29,955 · Tax withholding (F): 14,853 @ $27.33 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 9,444 · Tax withholding (F): 4,683 @ $29.85 · Option exercise (M): 9,444 (derivative) @ $0 | EDGAR |
| 2021-08-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 29,955 · Tax withholding (F): 14,853 @ $27.33 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 5,726 @ $0 | EDGAR |
| 2021-05-18 | 4 | Seagen Inc. (SGEN) | Grant/award (A): 1,402 @ $0 · Grant/award (A): 3,462 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Grant/award (A): 370 @ $36.21 · Grant/award (A): 132,433 (derivative) @ $0 · Grant/award (A): 75,556 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 42,018 · Tax withholding (F): 17,893 @ $49.49 · Option exercise (M): 12,063 (derivative) @ $0 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0 | EDGAR |
| 2020-08-18 | 4 | SEATTLE GENETICS INC /WA (SGEN) | Grant/award (A): 1,799 @ $0 · Grant/award (A): 4,460 (derivative) @ $0 | EDGAR |
| 2020-08-17 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,280 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1188919 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs